Breaking Down Shandong Sinobioway Biomedicine Co., Ltd. Financial Health: Key Insights for Investors

Investors looking for a clear snapshot of Shandong Sinobioway Biomedicine Co., Ltd. should note that Q1 2025 revenue was CNY 35.33 million (a 22.68% QoQ decline from CNY 45.69 million), contributing to a TTM revenue of CNY 257.74 million (down 36.54% YoY) and annual 2024 revenue of CNY 360.41 million (down 16.14%); the April 2025 suspension of production at Tianjin Sinobioway-which accounted for 60.09% of 2024 revenue-is a central driver of this slump. Profitability paints a strained picture: Q1 2025 net loss was CNY 36.85 million (versus a CNY 27.7 million loss in Q1 2024), TTM net loss totaled CNY 220.75 million with a net margin of -85.65% and EPS of -CNY 0.33, while gross margin remained high at 74.96% despite an EBITDA margin of -25.57%. The balance sheet shows low leverage-total debt CNY 6.31 million and debt-to-equity 0.32-against total assets of CNY 2.05 billion (down 9.66%) and total equity of CNY 1.94 billion; book value per share was CNY 2.869 with a P/B of 2.71. Liquidity metrics include a strong current ratio of 8.017 and total cash of CNY 445.01 million, offset by negative operating cash flow TTM of -CNY 49.96 million and levered free cash flow of -CNY 21.12 million. Market valuation as of December 12, 2025: market cap CNY 4.77 billion and P/S 20.99, with enterprise value CNY 4.46 billion (a 160.95% rise versus the four-quarter average). Key risks-production suspension, deeply negative margins, and negative operating cash flow-sit alongside growth levers such as R&D and patent holdings, recognition as a high-tech enterprise, and pipeline work on biologics and biosimilars; read on for a chapter-by-chapter deep dive into what these figures mean for investors.

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) - Revenue Analysis

Shandong Sinobioway Biomedicine's top-line trajectory through 2024-2025 shows material contraction tied to operational disruptions at a major subsidiary. Key figures and drivers are presented below.

• Q1 2025 revenue: CNY 35.33 million (down 22.68% vs. Q4 2024: CNY 45.69 million).
• 2024 annual revenue: CNY 360.41 million (down 16.14% vs. 2023: CNY 429.79 million).
• TTM revenue as of 2025-09-30: CNY 257.74 million (down 36.54% YoY).
• Market capitalization (2025-12-12): CNY 4.77 billion; P/S ratio: 20.99.

• Tianjin Sinobioway suspension: production halted in April 2025; this subsidiary contributed 60.09% of Shandong Sinobioway's revenue in 2024.
• The large revenue concentration in Tianjin Sinobioway means its suspension is the primary driver of the steep YoY and QoQ declines observed in 2025.

For related corporate positioning and strategic context, see Mission Statement, Vision, & Core Values (2026) of Shandong Sinobioway Biomedicine Co., Ltd.

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) - Profitability Metrics

Key profitability indicators for Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) show a company currently operating at a loss on a TTM basis despite strong gross margins, highlighting a gap between product-level profitability and overall operational performance.

• Recent quarterly trend: net loss widened from -CNY 27.7M (Q1 2024) to -CNY 36.85M (Q1 2025), signaling deteriorating near-term profitability.
• TTM performance: a cumulative net loss of -CNY 220.75M and EPS of -CNY 0.33 reflect sustained negative earnings across the last twelve months.
• Profitability ratios: ROE at -13.09% confirms shareholders are not currently seeing positive returns; net profit margin of -85.65% underscores heavy non-GS&A or financing/drug development expenses eroding bottom-line results.

Despite the losses, gross margin remains elevated at 74.96%, indicating strong unit economics before operating and other costs. The negative EBITDA margin of -25.57% suggests operating expenses and impairment/one-off charges are key drivers of the loss.

• Interpretation of mixed signals:
  • High gross margin: product-level profitability is strong, possibly due to pricing power or low COGS.
  • Negative EBITDA and net margins: scaling costs, R&D, SG&A, or financing costs are overwhelming gross profit.
• Investor considerations:
  • Watch quarterly operating expense trends, R&D capitalization, and any one-time charges that may normalize earnings.
  • Monitor liquidity and capital structure given sustained negative ROE and losses.

For background on the company's history, ownership and business model, see: Shandong Sinobioway Biomedicine Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) Debt vs. Equity Structure

• Low leverage: total debt of CNY 6.31 million against equity of CNY 1.94 billion yields a conservative financial risk profile (debt-to-equity 0.32).
• Asset contraction: total assets down 9.66% year-over-year to CNY 2.05 billion, signaling either asset disposals, depreciation, or slower asset growth.
• Liability reduction: total liabilities fell 7.53% YoY to CNY 107.31 million, consistent with deleveraging or lower short-term obligations.
• Equity dominance: equity comprises the vast majority of the balance sheet, supporting resilience to shocks and capacity for equity-funded initiatives.
• Per-share metrics: book value per share CNY 2.869 with P/B 2.71 - the market values the stock at a meaningful premium to book.

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) Liquidity and Solvency

Key liquidity and solvency indicators for Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) point to strong short-term reserves but stress in operating cash generation. The following highlights and figures summarize the company's current position.

• Current ratio (most recent quarter): 8.017 - indicating strong short-term liquidity and ability to cover current liabilities with current assets.
• Quick ratio: not specified - likely materially lower than the current ratio once inventory is excluded.
• Operating cash flow (TTM): -CNY 49.96 million - negative cash flow from operations over the trailing twelve months.
• Levered free cash flow (TTM): -CNY 21.12 million - negative free cash flow after debt service, signaling constraints on discretionary cash uses.
• Total cash (most recent quarter): CNY 445.01 million - a sizable cash cushion for near-term liquidity needs.
• Total debt / total assets: ≈ 0.31% - a very low level of leverage relative to asset base.

These metrics create a mixed picture: ample reported cash and exceptionally high current ratio contrast with negative operating and levered free cash flows, suggesting liquidity coverage now but potential vulnerability if negative operating trends persist. For additional context on ownership and market positioning, see Exploring Shandong Sinobioway Biomedicine Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) - Valuation Analysis

Key valuation and profitability metrics for Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) highlight a company currently priced with a high revenue multiple while reporting negative earnings and margins.

• Market capitalization (12 Dec 2025): CNY 4.77 billion; P/S ratio: 20.99.
• Enterprise value (Dec 2025): CNY 4.46 billion - a 160.95% increase vs. the 4-quarter average EV of CNY 1.71 billion.
• Price-to-book (P/B) (Jun 2025): 2.71.
• EPS (TTM): -CNY 0.33.
• Return on equity (ROE, TTM): -13.09%.
• Net profit margin (TTM): -85.65%.

Investor implications and valuation context can be further explored alongside the company's history, ownership and business model: Shandong Sinobioway Biomedicine Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) - Risk Factors

The following risk factors reflect material pressures on Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) based on recent operational events and trailing twelve months (TTM) financial metrics.

• Suspension of production at Tianjin Sinobioway in April 2025 has materially disrupted revenue streams, supply chain continuity, and client fulfillment, increasing short-term operational uncertainty.
• Negative profitability metrics indicate acute earnings stress: TTM net profit margin of -85.65% and TTM ROE of -13.09% signal that revenues are insufficient to cover costs and equity returns are negative.
• TTM EPS of -CNY 0.33 highlights per-share losses, which can depress investor confidence and restrict access to capital markets on favorable terms.
• TTM EBITDA margin of -25.57% implies core operations are cash-inefficient before financing and tax effects, pointing to potential restructuring needs or cost-control measures.
• Negative operating cash flow of -CNY 49.96 million over the TTM period raises liquidity and working capital concerns, particularly when combined with production suspension impacts.
• Operational concentration risk: a major subsidiary outage (Tianjin Sinobioway) can propagate revenue loss, contractual penalties, and customer attrition across the group.

• Immediate investor risks: potential covenant breaches, share dilution if capital raises are needed, and downward pressure on valuation multiples due to negative margins and cash flow.
• Medium-term operational risks: need for restart capital, remediation costs, lost contracts and renegotiation of supplier/customer terms following the Tianjin suspension.
• Market perception risks: persistent negative EPS and ROE may erode institutional investor interest and reduce stock liquidity.

Further context and investor-focused details are available here: Exploring Shandong Sinobioway Biomedicine Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) - Growth Opportunities

• R&D focus: sustained investment in biologics and biosimilars aimed at chronic indications (e.g., diabetes, autoimmune and cardiovascular therapy areas).
• Patent position: holds multiple patents related to biologic production processes and formulations, providing defensive moats for select pipeline assets.
• Institutional recognition: designated as a key high‑tech enterprise under the Torch Program and recognized as a high‑tech enterprise by provincial science, finance and taxation authorities.

• Commercialization pathways: partnering with larger pharma for distribution, pursuing domestic regulatory approvals, and exploring export opportunities as biosimilar markets expand.
• Funding and incentives: recognition under national and provincial programs can unlock R&D subsidies, tax relief, and preferential procurement opportunities.
• Operational leverage: provincial technology center and in‑house production know‑how reduce time‑to‑scale for manufacturing biologics compared with pure‑play virtual biotech models.